Twenty-six cases of Blastoschizomyces capitatus infection were diagnosed in 25 patients at 7 tertiary care hematology units in Spain over a 10-year period. Most patients (92%) had acute leukemia and developed infection during a period of severe and prolonged neutropenia. Two patients had esophagitis, and the rest had invasive infection. Fungemia (20 cases) was a common finding, with frequent visceral dissemination. The 30-day mortality associated with this infection was 52%, compared with 57% among patients with systemic infection. In a univariate analysis, the following 3 variables had a positive impact on 30-day survival: removal of the central venous catheter within 5 days after the onset of infection ( ), a good performance status P p .02 ( ), and receipt of systemic prophylactic or empirical antifungal therapy before infection onset ( P p .003 P p ). Outcome for neutropenic patients with B. capitatus infection is still poor. Rapid removal of the central .006 venous catheter and novel antifungal therapies are recommended for treatment of this rare infection.
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Invasive fungal infections pose a serious threat to patients treated for acute leukemia and to recipients of hematopoietic stem cell transplants. Most opportunistic fungal infections are still caused by Candida albicans, non-albicans species of Candida, and filamentous fungi of the genus Aspergillus. However, the spectrum of infecting species appears to be increasing, and many molds and yeasts have emerged as possible causes of invasive infection in patients with leukemia [1] [2] [3] [4] [5] . Among the emerging yeast pathogens, Blastoschizomyces capitatus is a rarely described yeast that produces severe systemic infection in such patients. Until now, most reports of infection caused by B. capitatus have described only a single case, with only 3 previous studies describing 12 cases [1, 6, 7] . Here, we report the results of a retrospective study performed in 7 tertiary-care hospitals in Spain that reported у1 case of B. capitatus infection from 1992 through 2002.
PATIENTS AND METHODS

Patients.
A survey was sent to 30 tertiary care hospitals in Spain to determine how many cases of B. capitatus infection were seen from 1992 through 2002. Eight hospitals reported having had 1-8 cases, and 7 of these centers agreed to fill out detailed case report forms, which serve as the basis of this study. Twentysix cases of infection were reported among 25 patients; 1 patient had 2 episodes of confirmed B. capitatus infection. Seventeen cases (65%) occurred during 1997-2001, and the remaining 8 cases occurred before 1997.
Definitions. To be included in this study, patients had to meet the criteria for a probable or proven invasive fungal infection caused by B. capitatus, as defined by the European Organization for the Research and Treatment of Cancer and Mycoses Study Group NOTE. ABLC, AmB lipid complex; ALL, acute lymphoblastic leukemia; AlloBMT, allogeneic bone marrow transplantation; Amik, amikacin; AML, acute myelogenous leukemia; APBSCT, autologous peripheral blood stem cell transplantation; Aug, augmentine; c-AmB, conventional amphotericin B; Chm, chemotherapy; CHOP, cyclophosphamide-doxorubicin-vincristine-prednisone; CMZ, cotrimoxazole; Cpfx, ciprofloxacin; CPL, chronic prolymphocytic leukemia; Ctri, ceftriaxone; Czid, ceftazidime; DAE, danorubicin-cytarabine-etoposide; DC, daunorubicin-cytarabine; ESHAP, etoposide-steroids-cytarabine-cisplatinum; Flu, fluconazole; IAE, idarubicin-cytarabine-etoposide; Imi, imipenem; Itr, itraconazole; L-AmB, liposomal AmB; MDS, myelodysplastic syndrome; Mero, meropenem; MitoAra-C, mitoxantrone-cytarabine; MM, multiple myeloma; mo, months; MOF, multiorgan failure; NA, not applicable; NHL, non-Hodgkin lymphoma; Pnt, pentostatin; Taz, piperacillin-tazobactam; Ter, terbinafine; Vm, vancomycin; Vor, voriconazole; 5-FC, 5-fluorocytosine.
(EORTC-MSG) groups [8] . In brief, isolation of B. capitatus in a culture of blood obtained from a febrile patient with or without signs of deep organ involvement was considered to be proven fungemia. Histological evidence of organ involvement plus a positive tissue culture result was evidence of proven invasive infection in the given organ, whereas radiological detection of lesions suggestive of organ involvement in a patient with fungemia but without documented pre-or postmortem histological confirmation was regarded as possible involvement of the given organ or organs. Patients with esophagitis had clinical, endoscopic, and microbiological documentation of infection. Patient 9, who had multilobar pneumonia, met the criteria of a probable pulmonary infection on the basis of the recovery of B. capitatus from several respiratory samples in the absence of other pathogens.
Microbiological methods. B. capitatus was formerly known as Trichosporon capitatum (previous cases were sometimes included in case series of trichosporonosis) and Geotrichum capitatum. All cases described in this article were identified as B. capitatus by microscopic detection of 3 types of conidia- arthroconidia, blastoconidia, and anneloconidia-as well as by characteristic carbohydrate assimilation patterns and other biochemical properties [9] .
Antifungal susceptibility testing for the azoles fluconazole and itraconazole was performed in 12 cases that occurred after 1996, in accordance with standardized guidelines developed by the NCCLS [10] or with a European modification of the NCCLS guidelines [11] . Susceptibilities to fluconazole, itraconazole, and 5-fluorocytosine were defined as MICs of !8 mg/L, !0.125 mg/L, and !4 mg/L, respectively; resistance cutoff values were 164 mg/L, 11 mg/L, and 132 mg/L, respectively. Values between these levels were considered to be intermediate susceptibilities.
Susceptibility to amphotericin B was also performed for 17 isolates, in accordance with NCCLS guidelines, with cutoff values for susceptibility and resistance of !1 mg/L and 12 mg/L, respectively. Values of 1-2 mg/L were considered to be intermediate levels of susceptibility.
Statistical analysis. Survival was calculated as the interval between onset of initial symptoms of B. capitatus infection and death from any cause or, for survivors, the time of final followup. Because all deaths that occurred within 30 days after the start of B. capitatus infection were attributed to this infection, 30-day survival probabilities were calculated using the KaplanMeier method, and curves were compared using the log-rank test. x 2 analysis or Fisher's exact test were used to establish differences in the distribution of categorical variables, and the Mann-Whitney U test was used to compare continuous variables. For survival analysis, patient 16 was included only once. Tests of significance were 2-sided, with a significance level of . P р .05 0.2 ϫ 10 The duration of severe neutropenia was a median of 7 days (range, 2-51 days) before infection and 8 days (range, 2-20 days) after infection. Twenty-three cases (88%) were in patients who had a central venous catheter that had been in place for a median of 18 days (range, 5-376 days) before infection. At the time of infection, 13 cases of infection (50%) were in patients who had a low performance status, defined as an Eastern Cooperative Oncology Group (ECOG) scale level of 2-4.
RESULTS
Patient
Nine cases of infection (35%) were in patients who had received systemic antifungal agents for at least 3 days before the onset of B. capitatus infection. These "breakthrough" infections occurred in patients who had been treated with amphotericin B (2 patients), itraconazole (1), and/or fluconazole (7). Additionally, 20 cases (77%) were in patients who had received broad-spectrum antibiotics for the treatment of febrile neutropenia for a median of 9 days (range, 1-24 days) before the onset of infection. At the time B. capitatus infection occurred or shortly thereafter, 6 patients had another life-threatening opportunistic infection, which included fungemia due to Candida kefyr in 1 patient, Candida lusitaniae in 1, and gramnegative bacteremia in 4.
Twenty-four cases of infection among 23 patients met the criteria for an invasive fungal infection; 2 patients had oropharyngeal and esophageal infection with B. capitatus. Fungemia was present in 20 patients; 3 patients without fungemia had proven (patient 8) or probable (patients 9 and 17) invasive infection. Fungemia lasted a median duration of 1 day (range, 1-10 days). Seven (35%) of the 20 patients with fungemia had positive results of blood cultures for у2 days after the onset of infection.
Additionally, patient 16 had fungemia during the neutropenic phase after undergoing an allogeneic bone marrow transplantation, which was apparently cured with antifungal therapy. The patient developed proven multiple spondylodiscitis due to B. capitatus infection 7 months after cure; this second episode was considered to be a reactivation of a latent infection during immunosuppression for treatment of graft-versus-host disease.
Antifungal therapy and outcome. All patients received systemic antifungal therapy after B. capitatus infection was diagnosed. The 2 patients (patients 1 and 2) with esophagitis received conventional amphotericin B plus oral itraconazole solution and showed complete resolution after 7 days of therapy. Both patients remained neutropenic for 17 days after they received their diagnoses, and no signs of dissemination occurred.
The other 23 patients (24 cases of infection) initiated antifungal therapy a median of 1 day (range, 0-30 days) after the onset of infection. In 12 cases of infection (46%), 148 h elapsed between the start of infection and the first dose of systemic antifungal therapy. The central venous catheter was removed in 14 (70%) of 20 patients with fungemia; in 6 patients, the catheter was left in place. The catheter was removed within 5 days after the start of fungemia for 7 of these 14 patients. Details on the antifungal therapy provided are listed in table 1. In summary, 12 patients received conventional amphotericin B therapy, 11 received a lipid formulation of amphotericin B, 6 received intravenous fluconazole, 4 received oral itraconazole, 4 received intravenous or oral voriconazole, 2 received oral terbinafine, 1 received caspofungin, and 1 received 5-fluorocytosine. Twelve patients received у2 antifungal drugs, either sequentially ( ) or in combination ( ). Because of the n p 4 n p 8 retrospective nature of the study and the small sample sizes, no correlations between outcome and the type of antifungal therapy could be made.
Thirteen patients died a median of 6 days (range, 1-25 days) after the start of infection. In all 13 cases, B. capitatus infection was considered to be the main cause of death. A postmortem examination was performed in 5 cases, the results of which confirmed disseminated multiorgan infection with B. capitatus in all cases. The other 10 patients responded to therapy, including the 2 patients with esophagitis. Univariate analysis of variables that influenced a successful outcome (defined as 30-day survival with eventual complete response to therapy) identified the following 3 variables as having a possible prognostic impact: (1) Antifungal sensitivity testing. Of the 12 specimens tested for sensitivity to fluconazole, 7 were considered resistant and 5 were considered susceptible. There were no apparent differences in the proportion of resistant strains among patients who had breakthrough infections while receiving therapy with an azole versus those with no previous exposure to these drugs (2 of 4 vs. 5 of 8 patients, respectively). Only 6 strains were tested for susceptibility to itraconazole. Five were susceptible, and 1 was intermediately susceptible. Again, 3 of 5 patients with susceptible strains were receiving an azole at the onset of infection. Eleven strains were susceptible to 5-fluorocytosine. Finally, of the 17 strains tested for susceptibility to amphotericin B, 13 were susceptible, 2 were resistant, and 2 intermediately susceptible. [1] (n p 16)
Herbrecht et al. [7] (n p 5)
Pé rez-Sá nchez et al. [6] (n p 4) 
DISCUSSION
This study represents the largest series of patients with probable or definite invasive infection with B. capitatus published to date. Overall, our results confirm the findings of the 3 previous reports that included 12 patients with this infection [1, 6, 7] . Table 2 shows the results of these 3 previous reports, compared with those of our current study. This opportunistic yeast infection mainly affects severely neutropenic patients with leukemia, and the clinical presentation is similar to that of invasive candidiasis in this patient group. Thus, most patients have fungemia, but the percentage of patients who develop clinically or microbiologically or histologically documented organ involvement is much higher than that among patients with candidiasis. Thus, 60%-80% of patients with B. capitatus infection develop deep organ involvement, compared with only 10%-20% of patients with candidemia [12] . The 30-day mortality attributable to B. capitatus infection also appears to be higher than that associated with candidemia (60% vs. 24%, respectively). An additional number of patients with B. capitatus infection will later die from persistent or recurrent infection-especially those with acute leukemia who are not in remission [1] -and the chance of obtaining a definite cure with antifungal therapy probably is 20%-33%, as seen in table 2. Infection with B. capitatus appears to more closely resemble infection with Trichosporon species in patients with leukemia, with common breakthrough infection, frequent fungemia with multiorgan dissemination, and a mortality rate of 60%-80% [3-5, 13, 14] Breakthrough infection accounted for 36% of the episodes of B. capitatus infection in our study, which is similar to the rate of 38% published by Martino et al. [1] more than a decade ago. This incidence is similar to the rate of breakthrough candidiasis among patients with hematological malignancies reported by Viscoli et al. [12] (40%) and Nucci et al. [15] (25%). Resistance to fluconazole [16] and liposomal amphotericin B [17] has been implicated in previous case reports of breakthrough infection with B. capitatus. However, other factors in addition to resistance to the drug being used may account for the occurrence of breakthrough infection, including pharmacokinetic problems, insufficient dose, and poor drug absorption. Unfortunately, we cannot give more insight on this issue, and we did not evaluate the absorption of fluconazole or itraconazole in blood. However, because many breakthrough infections were caused by strains susceptible in vitro to the drug being used, one may hypothesize that the above 3 problems may have been involved.
Univariate analysis revealed that previous receipt of antifungal therapy, a good performance status, and rapid removal of the central venous catheter were associated with a higher 30-day survival. Because the small sample size made a multi-variate analysis inappropriate, it is possible that these variables may be surrogate markers of other untested parameters and not the unfavorable variables themselves. For instance, a good performance status and rapid catheter removal may simply reflect a less severe underlying disease. On the other hand, it should be noted that previous receipt of antifungal therapy and a good performance status were also found to improve 30-day survival in a large candidemia survey by Viscoli et al. [12] . With respect to the drugs of choice for treating this infection, the heterogeneity of the drug combinations used in our study does not allow for any evidence-based suggestions. Some authors believe that B. capitatus has reduced susceptibility to amphotericin B [5, 18] . However, most of our strains were susceptible to this drug in vitro, and 12 of our 13 patients who were cured received amphotericin B therapy, either alone (5 patients) or in combination with other drugs (7 patients). Among the azoles, voriconazole and itraconazole appear to be more active in vitro than fluconazole [19, 20] . Most strains are susceptible to 5-fluorocytosine, but this drug is not suitable for patients with neutropenia. Thus, on the basis of our results and the in vitro data, we recommend combination therapy with voriconazole (or high-dose fluconazole for susceptible strains) plus amphotericin B, as suggested for the more common Trichosporon infections [3-5, 13, 14] .
